From December 21st to 24th, 2023, the Annual Meeting of Chinese College of Interventionalists (CCI 2023), organized by the Chinese Medical Doctors Association and the Interventional Physicians Branch, was held in Nanjing, Jiangsu Province. Fuda President Niu Lizhi was invited to deliver lectures titled "Brachytherapy Combined Ablation Treatment for Pancreatic Cancer" and "Applications and Reflects on Cryotherapy for Liver Cancer", and later was appointed as a member of the Expert Working Group on Brachytherapy by Committee. Likewhile, a paper on nanoknife treatment of locally advanced pancreatic cancer (LAPC), written by Ma Yangyang under the guidance of Prof. Niu awarded “2023 Outstanding English Performance”.
The CCI 2023 Annual Meeting features rich, comprehensive and cutting-edge when it comes to academic content. It has deepen cooperation with representatives from SIR (American Society of Interventional Radiology), CIRSE (Cardiovascular and Interventional Radiology Society Europe), APSCVIR (Asia-Pacific Society of Cardiovascular and Interventional Radiology) ) and other international/regional academic organizations, exchanging ideas on hot topics including interventional scientific research and development, theoretical and technological innovation, and clinical application transformation, as well as discussing worldwide cutting-edge findings and technologies.
CCI 2023 has received submissions from experts and scholars across the country. After committee discussion, the paper " Irreversible Electroporation Combined with Chemotherapy and PD-1/PD-L1 Blockade Enhanced Antitumor Immunity for Locally Advanced Pancreatic Cancer " written by Ma, a member of the Nanoknife team of Fuda, awarded “2023 Outstanding English Performance” and affirmed by Academician Teng Gaojun, the chairman of the conference.
Pancreatic cancer is a malignant tumor of the digestive tract that is highly malignant and difficult to diagnose and treat. Its incidence and mortality rate have increased significantly in recent years, ranking one of the malignant tumors with the worst prognosis and is known as the "King of Cancers", leading cancer death worldwide. However, with the continuous development of medical technology, nanoknife ablation of pancreatic cancer has attracted more and more attention. This awarded paper explains that Nanoknife can serve as a powerful trigger of immune response, promote the release of large amounts of tumor antigens hidden in cells, and become an "in situ tumor vaccine" to induce local and systemic immune responses. Besides, as a kind of "electro immune-modulatory therapy", Nanoknife has a synergistic effect when combined with immunotherapy. It is worth noting that preclinical research on Nanoknife combined with immunotherapy still requires in-depth exploration of its relevant mechanisms, and more large-scale, multi-center, prospective clinical data support is needed to confirm the best strategy (including time and dosage), so that can benefit more cancer patients.
This honor is not only recognition and encouragement to Ma and his team, but also an affirmation of the Fuda's academic research and practical exploration. Guangzhou Fuda Cancer Hospital has been introducing advanced technologies and equipment domestic and abroad, and provided personalized treatment according to the actual situation of patients. Among them, Fuda introduced the Nanoknife technology and successfully used in tumor treatment in July 2015, the same year as Nanoknife technology was approved for clinical use in China. At present, Fuda has published nearly 50 research papers related to Nanoknife, including more than 20 SCI papers. Work "New Technology for Tumor Ablation - Irreversible Electroporation" co-edited by Prof. Xu Kecheng and Prof. Niu Lizhi promoted the development of the medical academic community. In the future, Fuda will continue to improve medical technology and service quality, and fight for patients’ health.